

Special Issue

Current and Novel Antimicrobial Strategies for Bacterial and Fungal Infections by Resistant Organisms

Message from the Guest Editor

Dear colleagues, Resistance to common antimicrobials is one of the worst problems of our times. It represents a significant hurdle to an easy management of infection in many patients, especially the most vulnerable (e.g., immunosuppressed, those undergoing intensive care, children). Many factors have fuelled the widespread emergence of antimicrobial resistance among both Gram-negative and Gram-positive bacteria. Moreover, another element of concern is represented by resistance in fungi. For many years, the pipeline has not provided a valid response to this serious issue, but in recent times, novel compounds have enlarged the antimicrobial armamentarium. This Special Issue welcomes manuscript submissions that address the current and new strategies to deal with antimicrobial resistance in bacteria and fungi. **Keywords:** bacterial infections; fungal infections; multidrug-resistance; antibiotics; antifungals; antimicrobial stewardship; novel drugs

Guest Editor

Dr. Alberto Enrico Maraolo

Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy

Deadline for manuscript submissions

closed (31 October 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/62881

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)